220 related articles for article (PubMed ID: 21693597)
1. Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells.
Mian OY; Wang SZ; Zhu SZ; Gnanapragasam MN; Graham L; Bear HD; Ginder GD
Mol Cancer Res; 2011 Aug; 9(8):1152-62. PubMed ID: 21693597
[TBL] [Abstract][Full Text] [Related]
2. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
3. Methyl-CpG-binding protein MBD2 plays a key role in maintenance and spread of DNA methylation at CpG islands and shores in cancer.
Stirzaker C; Song JZ; Ng W; Du Q; Armstrong NJ; Locke WJ; Statham AL; French H; Pidsley R; Valdes-Mora F; Zotenko E; Clark SJ
Oncogene; 2017 Mar; 36(10):1328-1338. PubMed ID: 27593931
[TBL] [Abstract][Full Text] [Related]
4. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells.
Lin X; Nelson WG
Cancer Res; 2003 Jan; 63(2):498-504. PubMed ID: 12543808
[TBL] [Abstract][Full Text] [Related]
5. Methylated DNA binding domain protein 2 (MBD2) coordinately silences gene expression through activation of the microRNA hsa-mir-496 promoter in breast cancer cell line.
Alvarado S; Wyglinski J; Suderman M; Andrews SA; Szyf M
PLoS One; 2013; 8(10):e74009. PubMed ID: 24204564
[TBL] [Abstract][Full Text] [Related]
6. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma.
Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S
Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562
[TBL] [Abstract][Full Text] [Related]
7. MBD2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI.
Wang J; Li H; Qiu S; Dong Z; Xiang X; Zhang D
Cell Death Dis; 2017 Oct; 8(10):e3120. PubMed ID: 29022913
[TBL] [Abstract][Full Text] [Related]
8. The "Methyl-CpG Binding Domain protein 2" plays a repressive role in relation to the promoter CpG content in the normal human cell line MRC5.
Perriaud L; Lachuer J; Dante R
Curr Pharm Des; 2014; 20(11):1598-603. PubMed ID: 23888954
[TBL] [Abstract][Full Text] [Related]
9. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
10. MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland.
Billard LM; Magdinier F; Lenoir GM; Frappart L; Dante R
Oncogene; 2002 Apr; 21(17):2704-12. PubMed ID: 11965543
[TBL] [Abstract][Full Text] [Related]
11. Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition.
Mahmood N; Arakelian A; Szyf M; Rabbani SA
Exp Mol Med; 2024 Apr; 56(4):959-974. PubMed ID: 38556549
[TBL] [Abstract][Full Text] [Related]
12. Preferential binding of the methyl-CpG binding domain protein 2 at methylated transcriptional start site regions.
Chatagnon A; Perriaud L; Nazaret N; Croze S; Benhattar J; Lachuer J; Dante R
Epigenetics; 2011 Nov; 6(11):1295-307. PubMed ID: 22048253
[TBL] [Abstract][Full Text] [Related]
13. Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
Manjegowda MC; Gupta PS; Limaye AM
Gene; 2017 May; 614():65-73. PubMed ID: 28286086
[TBL] [Abstract][Full Text] [Related]
14. Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression.
Ghoshal K; Majumder S; Datta J; Motiwala T; Bai S; Sharma SM; Frankel W; Jacob ST
J Biol Chem; 2004 Feb; 279(8):6783-93. PubMed ID: 14610093
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
16. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells.
Bakker J; Lin X; Nelson WG
J Biol Chem; 2002 Jun; 277(25):22573-80. PubMed ID: 11960994
[TBL] [Abstract][Full Text] [Related]
17. Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells.
Chatagnon A; Bougel S; Perriaud L; Lachuer J; Benhattar J; Dante R
Carcinogenesis; 2009 Jan; 30(1):28-34. PubMed ID: 18952593
[TBL] [Abstract][Full Text] [Related]
18. Specific binding of the methyl binding domain protein 2 at the BRCA1-NBR2 locus.
Auriol E; Billard LM; Magdinier F; Dante R
Nucleic Acids Res; 2005; 33(13):4243-54. PubMed ID: 16052033
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
Sidiropoulos M; Pampalakis G; Sotiropoulou G; Katsaros D; Diamandis EP
Tumour Biol; 2005; 26(6):324-36. PubMed ID: 16254462
[TBL] [Abstract][Full Text] [Related]
20. MBD3L2 interacts with MBD3 and components of the NuRD complex and can oppose MBD2-MeCP1-mediated methylation silencing.
Jin SG; Jiang CL; Rauch T; Li H; Pfeifer GP
J Biol Chem; 2005 Apr; 280(13):12700-9. PubMed ID: 15701600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
